Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation
- PMID: 23190066
- DOI: 10.1586/erc.12.113
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation
Abstract
Percutaneous coronary intervention is evolving rapidly. Among the developments in various aspects, dual antiplatelet therapy (DAPT) has played a pivotal role to reduce thrombotic events after stent implantation. After the introduction of the drug-eluting stent, prolonged DAPT has been recommended due to concerns regarding late and very late stent thrombosis. However, there are controversies regarding the benefit of long-term DAPT. In addition, prolonged DAPT accompanies increased bleeding risk as well as additional cost. To balance the benefit and risk, optimizing DAPT duration is crucial. In this article, clinical guidelines and studies regarding optimal duration of DAPT are discussed.
Similar articles
-
Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.Catheter Cardiovasc Interv. 2012 Sep 1;80(3):395-405. doi: 10.1002/ccd.23337. Epub 2012 Jan 10. Catheter Cardiovasc Interv. 2012. PMID: 22109961
-
Dual antiplatelet therapy after drug-eluting stents: defining the proper duration.Coron Artery Dis. 2014 Jan;25(1):83-9. doi: 10.1097/MCA.0000000000000066. Coron Artery Dis. 2014. PMID: 24322887 Review.
-
Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: a review of the current guidelines and literature.Hosp Pract (1995). 2011 Oct;39(4):32-40. doi: 10.3810/hp.2011.10.920. Hosp Pract (1995). 2011. PMID: 22056821 Review.
-
Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.Eur Heart J. 2012 Dec;33(24):3078-87. doi: 10.1093/eurheartj/ehs318. Epub 2012 Oct 22. Eur Heart J. 2012. PMID: 23091199 Review.
-
Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials.Cardiovasc Ther. 2015 Oct;33(5):253-63. doi: 10.1111/1755-5922.12137. Cardiovasc Ther. 2015. PMID: 26010419
Cited by
-
Randomized comparison of acute stent malapposition between platinum-chromium versus cobalt-chromium everolimus-eluting stents.Int J Cardiovasc Imaging. 2015 Feb;31(2):269-77. doi: 10.1007/s10554-014-0557-y. Epub 2014 Oct 28. Int J Cardiovasc Imaging. 2015. PMID: 25345751 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical